Close this search box.

Who decides which medications are available to the 5 million Americans living with Alzheimer’s?

Increasingly, questions of access are informed by the Institute for Clinical and Economic Review, or ICER. The health economics organization uses clinical trials data and available pricing information to consider whether a drug is worth its cost.

Now, ICER is reviewing a new treatment for Alzheimer’s disease. ICER’s upcoming review will examine a medication, Aducanumab, that could be the first disease modifying treatment approved to treat Alzheimer’s disease.

Get Involved

ICER’s reports can influence health plans’ decisions about coverage. Input from advocacy organizations, health care providers and patients is critical.

Register for ICER’s Public Meeting

ICER will host a public meeting on July 15 to deliberate and vote on evidence presented in their report on Alzheimer’s disease.

Share Social Media Graphics

To download and share: Click an image above, then right click and choose “save image as”. Choose a destination on your computer, such as your desktop or a folder, and click save. Then, post to Facebook or Twitter just as you would any other image.

Tweet & Post to Raise Awareness

Learn More

Who Will Control Access to New Alzheimer’s Treatments?

An Institute for Patient Access blog explains that a “poorly structured review could delay patient access to this – and future – treatments that represent the best hope yet against this still incurable disease.”

Read Blog >>

ICER’s Evaluation of Alzheimer’s Treatment Undervalues Key Groups

The Institute for Clinical and Economic Review claims that the first disease-modifying treatment for Alzheimer’s disease isn’t worth its cost. But the economists omit several key considerations about the devastating neurodegenerative disease.

View Graphic >>

Leave a Reply

Your email address will not be published. Required fields are marked *